Citations

Showing 10 of 108104 citations.

Predictive Model for Medical and Surgical Readmissions Following Elective Lumbar Spine Surgery
Sivaganesan, Ahilan, Khan, Inamullah , Nian, Hui , Pennings, Jacquelyn S. , Foley, Kevin T. , Bydon, Mohamad , Asher, Anthony L. , Devin, Clinton J. , Archer, Kristin R. , Zuckerman, Scott L. , Harrell, Frank E. , Harbaugh, Robert E.

Mayo Clinic

Spine | September 28, 2018 | Volume: 44 | Issue: 8 | Pages: 588-600

10.1097/brs.0000000000002883 | PMID 30247371 Get It

Study Design. This study retrospectively analyzes prospectively collected data. Objective. Here we aim to develop predictive models for 3-month medical and surgical readmission after elective lumbar surgery, based on a multi-institutional, national spine registry. Summary of Background Data. Unplanned readmissions place considerable stress on payers, hospitals, and patients. Medicare data reveals a 30-day readmission rate of 7.8% for lumbar-decompressions and 13.0% for lumbar-fusions, and hospitals are now being penalized for excessive 30-day readmission rates by virtue of the Hospital Readmissions Reduction Program. Methods. The Quality and Outcomes Database (QOD) was queried for patients undergoing elective lumbar surgery for degenerative diseases. The QOD prospectively captures 3-month readmissions through electronic medical record (EMR) review and self-reported outcome questionnaires. Distinct multivariable logistic regression models were fitted for surgery-related and medical readmissions adjusting for patient and surgery-specific variables. Results. Of the total 33,674 patients included in this study 2079 (6.15%) reported at least one readmission during the 90-day postoperative period. The odds of medical readmission were significantly higher for older patients, males versus females, African Americans versus Caucasion, those with higher American Society of Anesthesiologists (ASA) grade, diabetes, coronary artery disease, higher numbers of involved levels, anterior only or anterior–posterior versus posterior approach; also, for patients who were unemployed compared with employed patients and those with high baseline Oswestry Disability Index (ODI). The odds of surgery-related readmission were significantly greater for patients with a higher body mass index (BMI), a higher ASA grade, female versus male, and African Americans versus Caucasians; also, for patients with severe depression, more involved spinal levels, anterior-only surgical approaches and higher baseline ODI scores. Conclusion. In this study we present internally validated predictive models for medical and surgical readmission after elective lumbar spine surgery. These findings set the stage for targeted interventions with a potential to reduce unnecessary readmissions, and also suggest that medical and surgical readmissions be treated as distinct clinical events. Level of Evidence: 3
Impact of changes to donor hemoglobin criteria on the rate of donor deferral
Perez, Gabriela, Whitaker, Barbee , Vassallo, Ralph R. , Stubbs, James R. , Vassallo, Ralph R , Gammon, Richard R.

Mayo Clinic

Transfusion | September 28, 2018 | Volume: 58 | Issue: 11 | Pages: 2581-2588

10.1111/trf.14950 | PMID 30264396 Get It

BACKGROUND The Food and Drug Administration's requirements for “Blood and Blood Components Intended for Transfusion or Further Manufacturing Use” (Final Rule) effective May 2016 changed eligibility criteria for blood donors. A multivariate analysis was performed to measure its impact on donor deferral rates. STUDY DESIGN AND METHODS Four blood centers submitted data for similar 6‐month periods before and after implementation of the Final Rule. Data included presenting donors, units collected, deferrals, intended products from deferred donors, deferral reasons, presenting donor demographics, donor hemoglobin (Hgb), hematocrit (HCT), pulse, blood pressure (BP), temperature, and other reasons for deferral. Data were aggregated and periods compared. RESULTS After Final Rule implementation, successful donations decreased by 1.3% (83.1%‐81.9%), despite a 0.2% increase in presenting donors. The rate of Hgb/HCT, pulse, and deferrals increased, while deferrals for other reasons decreased. Male Hgb/HCT deferral rates increased 1.2% (4213 total). Black male donors' Hgb/HCT deferral rate increased (2.7%‐5.2%) but was counterbalanced by an overall 3.7% decrease in black female Hgb/HCT deferrals. While Hgb/HCT deferrals of black donors remained stable overall (17.0% vs. 16.2%), this trend was not observed by all centers. Deferrals for pulse increased (0.2%), as did BP deferrals (0.2%). CONCLUSION Although there was a small increase in presenting donors after implementation of the Final Rule, there was a decrease in successful donations. While it appeared that deferral in black donors was unchanged, this trend was not observed across all centers. Pulse and BP deferrals rose dissimilarly among centers, according to individual procedures.
The Republic of Malta and endoscopic eradication therapy for Barrett’s esophagus
Fleischer, David, Fleischer, David E.

Mayo Clinic

Endoscopy | September 27, 2018 | Volume: 50 | Issue: 10 | Pages: 943-945

10.1055/a-0662-5584 | PMID 30261539 Get It

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Johnston, Patrick B. , Atherton, Pamela J., Pederson, Levi , Koenig, Patricia, Reeder, Craig B. , Omuro, Antonio Marcilio Padula , Schiff, David , Pulido, José S. , Jaeckle, Kurt A. , Grommes, Christian , Atherton, Philip J. , Tun, Han W. , Pederson, Levi D , Koenig, Patricia A, Omuro, Antonio M Padula , Schiff, David , O'Neill, Brian, Pulido, Jose, DeAngelis, Lisa M. , Atherton, Pamela J., O’Neill, Brian Patrick , Witzig, Thomas E. , Atherton, Philip J.

Mayo Clinic

Blood | September 27, 2018 | Volume: 132 | Issue: 21 | Pages: 2240-2248

10.1182/blood-2018-02-835496 | PMID 30262659 Get It

AbstractThe combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives. A cohorts-of-3 study design was used with a dose-escalation schedule consisting of POM (3, 5, 7, or 10 mg) orally daily for 21 days every 28 days and DEX 40 mg orally every week. After 2 cycles, POM was continued alone until disease progression, intolerance, or subject withdrawal. Following MTD determination, the MTD cohort was expanded. Twenty-five of 29 patients with the median of 3 prior treatments were eligible for assessment as per international PCNSL collaborative group criteria. The MTD of POM was 5 mg daily for 21 days every 28 days. Whole-study ORR was 48% (12 of 25; 95% confidence interval [CI], 27.8%, 68.7%) with 6 complete response (CR), 2 complete response, unconfirmed (CRu), and 4 partial response (PR). MTD cohort ORR was 50% (8 of 16; 95% CI, 24.7%, 75.4%) with 5 CR, 1 CRu, and 2 PR. Median PFS was 5.3 months (whole study) and 9 months (for responders). One patient had pseudoprogression. Grade 3/4 hematologic toxicities included neutropenia (21%), anemia (8%), and thrombocytopenia (8%). Grade 3/4 nonhematologic toxicities included lung infection (12%), sepsis (4%), fatigue (8%), syncope (4%), dyspnea (4%), hypoxia (4%), respiratory failure (8%), and rash (4%). POM/DEX treatment is feasible with significant therapeutic activity against relapsed/refractory PCNSL and PVRL. This trial was registered at www.clinicaltrials.gov as #NCT01722305.
Comparison of Oral Collection Methods for Studies of Microbiota
Vogtmann, Emily , Chen, Jun , Amir, Amnon , Shi, Jianxin , Chen, Yu , Eunes, Mahbubul, Ahmed, Alauddin , Naher, Jabun, Rahman, Anisur, Barmon, Bhaswati, Knight, Rob , Ahsan, Habibul , Abnet, Christian C. , Chia, Nicholas , Abnet, Christian C , Kibriya, Muhammad Ghulam , Islam, Tariqul , Chia, Nicholas , Sinha, Rashmi R. , Chen, Yu

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 27, 2018 | Volume: 28 | Issue: 1 | Pages: 137-143

10.1158/1055-9965.epi-18-0312 | PMID 30262598 Get It

Abstract Background: A number of cohort studies have collected Scope mouthwash samples by mail, which are being used for microbiota measurements. We evaluated the stability of Scope mouthwash samples at ambient temperature and determined the comparability of Scope mouthwash with saliva collection using the OMNIgene ORAL Kit. Methods: Fifty-three healthy volunteers from Mayo Clinic and 50 cohort members from Bangladesh provided oral samples. One aliquot of the OMNIgene ORAL and Scope mouthwash were frozen immediately and one aliquot of the Scope mouthwash remained at ambient temperature for 4 days and was then frozen. DNA was extracted and the V4 region of the 16S rRNA gene was PCR amplified and sequenced using the HiSeq. Intraclass correlation coefficients (ICC) were calculated. Results: The overall stability of the Scope mouthwash samples was relatively high for alpha and beta diversity. For example, the meta-analyzed ICC for the Shannon index was 0.86 (95% confidence interval, 0.76–0.96). Similarly, the ICCs for the relative abundance of the top 25 genera were generally high. The comparability of the two sample types was relatively low when measured using ICCs, but were increased by using a Spearman correlation coefficient (SCC) to compare the rank order of individuals. Conclusions: Overall, the Scope mouthwash samples appear to be stable at ambient temperature, which suggests that oral rinse samples received by the mail can be used for microbial analyses. However, Scope mouthwash samples were distinct compared with OMNIgene ORAL samples. Impact: Studies should try to compare oral microbial metrics within one sample collection type.
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements
Luchtel, Rebecca A. , Dasari, Surendra , Pedersen, Martin Bjerregård , Hu, Guangzhen , Sidhu, Jagmohan S. , Katoh, Ryohei, Kip, N. Sertac, Cunningham, Julie M. , Sun, Zhifu , Baheti, Saurabh , Porcher, Julie C., Said, Jonathan , Jiang, Liuyan , Hamilton‐Dutoit, Stephen , Møller, Michael , Nørgaard, Peter , Link, Brian K. , d’Amore, Francesco, Ansell, Stephen M. , Hamilton-Dutoit, Stephen Jacques , Møller, Michael Boe , Feldman, Andrew L , Sun, Zhifu , Link, Brian K , Oishi, Naoki , Rech, Karen L. , Ketterling, Rhett P. , Wang, Xueju , Doǧan, Ahmet , Bennani, N. Nora , Chng, Wee Joo , Huang, Gaofeng , Facchetti, Fabio , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | September 27, 2018 | Volume: 132 | Issue: 13 | Pages: 1386-1398

10.1182/blood-2018-03-838524 | PMID 30093402 Get It

Key PointsDUSP22-rearranged ALCLs belong to a distinct subset of ALCLs lacking activated STAT3. DUSP22-rearranged ALCLs have a unique molecular signature characterized by DNA hypomethylation and an immunogenic phenotype.
Pediatric Periocular Dermoid Cysts: Incidence, Clinical Characteristics, and Surgical Outcomes
Bajric, Jasmina, Griepentrog, Gregory J. , Mohney, Brian G.

Mayo Clinic

Ophthalmic Epidemiology | September 27, 2018 | Volume: 26 | Issue: 2 | Pages: 117-120

10.1080/09286586.2018.1525412 | PMID 30260262 Get It

Use of online symptom checkers to delineate the ever‐elusive GERD versus non‐GERD cough
Berry, Andrew C. , Berry, Nicholas A. , Wang, Bin , Mulekar, Madhuri S. , Melvin, Anne, Battiola, Richard J., Bulacan, Frederick K., Berry, Bruce B.

Mayo Clinic

The Clinical Respiratory Journal | September 27, 2018 | Volume: 12 | Issue: 12 | Pages: 2683-2685

10.1111/crj.12966 | PMID 30260573 Get It

Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States
Theel, Elitza S. , Aguero‐Rosenfeld, Maria E. , Pritt, Bobbi S. , Adem, Patricia , Wormser, Gary P. , Pritt, Bobbi, Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | September 27, 2018 | Volume: 57 | Issue: 1 | Pages: No page available

10.1128/jcm.01406-18 | PMID 30257905 Get It

In the United States, laboratories frequently offer multiple different assays for testing of cerebrospinal fluid (CSF) samples to provide laboratory support for the diagnosis of central nervous system Lyme disease (CNSLD). Often included among these diagnostic tests are the same enzyme immunoassays and immunoblots that are routinely used to detect the presence of antibodies to Borrelia burgdorferi in serum.
Nitazoxanide Is a Therapeutic Option for Adenovirus-Related Enteritis in Immunocompromised Adults
Garrigos, Zerelda Esquer , Hamdi, Ahmed , Saleh, Omar Abu , Sohail, M. Rizwan , Esquer Garrigos, Zerelda , Barth, Dylan , Hamdi, Ahmed M , Abu Saleh, Omar M, Sohail, M Rizwan , Barth, Dylan

Mayo Clinic

Antimicrobial Agents and Chemotherapy | September 27, 2018 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/aac.01937-18 | PMID 30275085 Get It